How safe are anti-rheumatic drugs during pregnancy?
Graphical abstract
Introduction
Planning pregnancy in women with rheumatic diseases requires adjustment of therapy to drugs, which keep the underlying maternal disease quiescent and are compatible with embryonic and fetal development. Withdrawal of all drugs administered before conception resulting in a disease flare may be equally disastrous for pregnancy outcome as continuation of agents that are able to harm the developing child.
Information on usage of drugs during pregnancy is limited, since pregnant women are never included in drug trials and knowledge usually accumulates over the years from inadvertent drug exposure during unplanned pregnancies. Regular updates of information are therefore timely. This survey is based on a literature search on immunosuppressive, antirheumatic drugs used in pregnancy published during 2010–2012. Several excellent reviews have given a complete overview of published experience of antirheumatic drugs in pregnancy, and these should be consulted for details [1•, 2, 3].
Risks of pregnancy in the mother with rheumatic disease depend on disease activity shortly before conception and throughout pregnancy, extent of organ involvement and presence of certain types of autoantibodies (Table 1). Risks for the fetus are related to maternal disease activity, presence of autoantibodies and maternal therapy (Table 1). As shown in Table 2, drug therapy of rheumatic diseases differs and will as a rule be tailored according to type of organ involvement, severity of the disease and individual response to treatment. Adjustment of therapy in a patient planning a pregnancy or consulting during early pregnancy will aim at optimal disease control in the mother and healthy development of the child (Figure 1).
Methotrexate (MTX) and cyclophosphamide (CYC) inhibit cell division and are teratogenic in animals and humans. No new reports on CYC in autoimmune disease pregnancies have been located. A teratogen update has analyzed all the published cases with MTX exposures to doses between 7.5 mg/week for rheumatic diseases and up to 150 mg/week for induction of abortion for the proportion of all malformations [4••] and compared with the same proportion from the Metropolitan Atlanta Congenital Defects Program [5]. The data have confirmed that the sensitive period for the production of malformations is 6–8 weeks after conception for doses greater than 10 mg of MTX/week. Higher doses increase the risk for MTX embryopathy including cardiac defects, pulmonary atresia, craniosynostosis, and limb deficiencies [4••].
Two new studies have addressed pregnancy outcomes in men treated with MTX. A prospective study of men treated with weekly doses 7.5 mg and 30 mg of MTX three months before or until conception found no child with birth defects in 42 pregnancies [6]. A population based study of 50 pregnancies with fathers exposed to MTX has reported two children with orofacial malformations [7].
Mycophenolate (MMF) is used successfully in the treatment of lupus nephritis. First trimester exposure increases the risk for multiple congenital malformations with a special phenotype including microtia, auditory canal atresia, cleft lip and palate, micrognathia, hypertelorism, ocular coloboma, short fingers and hypoplastic nails [8]. A new prospective study has investigated 57 pregnancies exposed to MMF in the first trimester [9]. 45% of the pregnancies ended in spontaneous abortion. Six out of 29 live born children showed congenital malformations, which in four infants had a clinical phenotype consistent with mycophenolate embryopathy [9]. The malformation rate for all the pregnancies after MMF exposure was 26%. Patients who start treatment must be informed that discontinuation of MMF is necessary at least 6 weeks before trying conception, and be advised to use effective birth control during therapy.
Leflunomide, an inhibitor of pyrimidine synthesis was shown to be teratogenic in rats, rabbits and mice, and therefore labeled as contraindicated in human pregnancy [10]. A few case reports during the years 2000–2010 were not conclusive until the Organization of Teratology Information Specialists (OTIS) published the results of a prospective study of birth outcomes in women exposed before or during pregnancy to leflunomide [11••]. Comparing pregnancy outcomes of 64 patients with RA exposed during the first trimester to 108 RA pregnancies not exposed neither showed increase in birth defects nor any recognizable malformation pattern [11••]. This result was confirmed in additional 45 pregnancies of patients who were exposed to leflunomide either within two years before conception or during the first trimester [12]. These data indicate that leflunomide is not a strong human teratogen though due to the limited number of exposed pregnancies contraception is recommended during use and a washout procedure in case of a planned or unintended pregnancy.
A controversy exists as to an association of first trimester exposure to corticosteroids and a significant increase of oral clefts [13]. A new population based study with 51 973 corticosteroid exposed pregnancies did not find an increase of orofacial clefts regardless of type of corticosteroid administered (oral, inhalation, nasal spray, topical) [14••]. After completion of placenta development, all corticosteroids are partly inactivated by 11-beta-hydroxylases of the placenta with relative protection of the fetus. Prolonged use of corticosteroids increases the risk of preterm delivery, intrauterine growth restriction, and the frequency of maternal side effects like hypertension, diabetes mellitus and osteoporosis. However, severe flares of rheumatic disease during pregnancy most often need doses of corticosteroids exceeding 20 mg/day for rapid control of symptoms.
Hydroxychloroquine (HCQ) exerts a number of positive effects that are particularly beneficial for SLE patients [15]. These include prevention of lupus flares, lowering of lipid levels, and moderate protections against thrombosis [16], and reduction of development of congenital heart block (CHB) in children of mothers positive for anti-Ro/anti-La antibodies [17]. Even in anti-Ro/anti-La positive mothers with a previous child with CHB the recurrence rate of cardiac-NL was 64.6% lower in pregnancies exposed to HCQ compared with those unexposed [18]. The new data indicate that HCQ should be continued in SLE patients and other patients positive for anti-Ro/anti-La antibodies throughout pregnancy.
A registry based Norwegian study has identified 589 pregnancies with exposure to antirheumatic drugs during the first trimester, thereof 74 exposed to sulfasalazine. No increase in congenital malformations was found in exposed children [7], confirming previous studies.
Cyclosporine (Cs) and tacrolimus are calcineurin inhibitors and inhibit the activation of T and B cells. Two forms of cyclosporine with different bioavailabilities are available: CsA and modified Cs (Neoral) the latter with much improved bioavailability. Most pregnancy experience is present for CsA and stems from registries of pregnant transplant recipients whereas experience from pregnant patients with autoimmune disease is limited to case reports and case series. Thus far, most of the studies of pregnancies exposed to CsA or Neoral have found an increase in premature delivery and low birth weight, but no increase of congenital malformations nor any particular malformation pattern [19, 20]. Whether prematurity and low birth weight actually are a side effect of Cs or related to the underlying disease and comorbidities or multidrug therapy is not clarified. Pregnancy experience for tacrolimus is nearly exclusively related to transplant recipients, but a few case reports on patients with autoimmune diseases exist [20, 21]. As with Cs no increase in the malformation rate or a malformation pattern has emerged. In patients with autoimmune disease refractory to other immunosuppressive treatment Cs or tacrolimus may be administered during pregnancy.
In a systematic review and meta-analysis the effect of thiopurines (6-mercaptopurine and azathioprin) on birth outcome from female and male inflammatory bowel disease (IBD) patients were analyzed [22••]. The pooled analysis of five studies showed no significant association between thiopurines and congenital defects (OR 1.45; 95% CI 0.99, 2.13) or low birth weight (OR 1.01; 95% CI 0.96, 1.06). However, the analysis disclosed a significant increase for the association between preterm birth and women taking thiopurines (OR 2.28; 95% CI 0.67, 7.73), yet it remains unclear whether this was secondary to the drug or to active IBD [22••]. The findings confirm results in transplant recipients treated with AZA and support its use during pregnancy when indicated.
The pooled analysis of three studies showed no significant risk for congenital anomalies after paternal exposure at the time of conception to thiopurines [22••]. Another study evaluated the outcome of 46 pregnancies when fathers were exposed to thiopurines [23]. No significant difference in regard to unsuccessful pregnancies or congenital malformations was found compared with pregnancies fathered by patients who had never been treated with thiopurines or who stopped thiopurines more than 3 months before conception.
Section snippets
TNF inhibitors: monoclonal antibodies infliximab, adalimumab and golimumab
The publications between 2010 and 2012 have by and large confirmed previous data on the use of infliximab, and adalimumab in pregnancy showing no increased risk of congenital malformations [24]. There are at present no human data for golimumab. TNF inhibitors that are complete antibodies containing an Fc part of IgG1 are actively transported through the placenta and reach high blood levels in the newborn after exposure in the late second and in the third trimester. Since the half-life of
Conclusion
The survey confirms by and large the results on the safety of antirheumatic drugs during pregnancy that emerged in previous studies [1•, 2, 3]. New data have confirmed that leflunomide is not a human teratogen though washout procedures before conception or during an unplanned pregnancy are still recommended. The leflunomide data underscore the importance of prospective studies following the OTIS design: comparison of pregnancy outcomes in patients exposed versus patients not-exposed and
Disclosure
Monika Østensen has received speaker fees from Mepha; MSD; Pfizer; Roche; and UCB, Inc. Frauke Förger has received speaker fees from Roche and UCB.
References and recommended reading
Papers of particular interest, published within the period of review, have been highlighted as:
• of special interest
•• of outstanding interest
References (33)
- et al.
Case report: fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's disease
J Crohns Colitis
(2010) - et al.
Reversible male infertility under treatment with an anti-TNFα agents: a case report
Ann Rheum Dis
(2012) - et al.
Anti-inflammatory and immunosuppressive drugs and reproduction
Arthritis Res Ther
(2006) - et al.
Management of RA medications in pregnant patients
Nature Rev Rheumatol
(2009) - et al.
Rheumatoid arthritis and pregnancy: evolution of disease activity and pathophysiological considerations for drug use
Rheumatology (Oxford)
(2011) - et al.
Teratogen update: methotrexate
Birth Defects Res
(2012) - et al.
Metropolitan Atlanta congenital defects program 40th Anniversary Edition Surveillance Report, Appendix A
Birth Defects Res (A)
(2007) - et al.
Paternal exposure to methotrexate and pregnancy outcomes
J Rheumatol
(2011) - et al.
Outcomes after anti-rheumatic drug use before and during pregnancy: a cohort study among 150,000 pregnant women and expectant fathers
Scand J Rheumatol
(2012) - et al.
Reviewing the evidence for mycophenolate mofetil as a new teratogen: case report and review of the literature
Am J Med Genet A
(2009)
Teratogenicity of mycophenolate confirmed in a prospective study of the European Network of Teratology Information Services
Am J Med Genet A
Teratogen update: reproductive risks of leflunomide (Arava), a pyrimidine synthesis inhibitor: counseling women taking leflunomide before or during pregnancy and men taking leflunomide who are contemplating fathering a child
Teratology
Birth outcomes in women who have taken leflunomide during pregnancy
Arthritis Rheum
Pregnancy outcome in women exposed to leflunomide before or during pregnancy
Arthritis Rheum
Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies
Teratology
Corticosteroid use during pregnancy and risk of orofacial clefts
Can Med Ass J
Cited by (81)
Contraceptive use and counseling in patients with systemic lupus erythematosus
2022, ContraceptionCitation Excerpt :Patients with SLE have an increased risk of complications during pregnancy, including maternal risks (disease flare, progression of renal disease, gestational diabetes, deep vein thrombosis, and pre-eclampsia), as well as fetal risks (miscarriage, intrauterine fetal demise, intrauterine growth restriction, and preterm birth) [1-4]. Additionally, many medications used to treat SLE have demonstrated or potential teratogenicity, such as mycophenolate, cyclophosphamide, methotrexate, warfarin, and immunomodulators [5-9]. Pregnancy outcomes in women with SLE can be significantly improved with careful pregnancy timing.
Management of Pregnancy in Lupus
2021, Rheumatic Disease Clinics of North AmericaCitation Excerpt :Leflunomide is the exception and requires an intensive cholestyramine washout protocol for elimination.55 Fortunately, many therapeutics for the management of SLE are compatible with pregnancy and their use is supported by numerous observational studies without evidence of increased risk of congenital anomalies.53 Expert consensus and guidelines strongly recommend that use of these medications to control disease is critical to minimizing APO because active disease in the periconception pregnancy period is strongly associated with adverse outcomes in both mother and fetus.30,54
Management of dermatological conditions in pregnancy
2021, Clinical Pharmacology During PregnancyPregnancy and Kidney Disease
2019, Chronic Renal DiseaseTacrolimus treatment in women with repeated implantation failures
2024, Reproductive Medicine and Biology